title: Outcomes of balloon dilation for the treatment of strictures after endoscopic submucosal dissection compared with peptic strictures.
abstract: BACKGROUND
  The outcomes of balloon dilation for the treatment of strictures caused by endoscopic submucosal dissection (ESD) have not been evaluated previously. This study was designed to evaluate and compare the effectiveness and complications of balloon dilation for post-ESD strictures and peptic strictures.
  
  
  METHODS
  The medical records of 14 patients with post-ESD strictures and 48 patients with peptic strictures who underwent fluoroscopically or endoscopically guided balloon dilation between January 1997 and April 2011 at the Asan Medical Center in Korea were reviewed retrospectively.
  
  
  RESULTS
  The technical success rates (defined as successful dilation without major complications) of the post-ESD and peptic stricture groups were 92.9% (13/14) and 93.8% (45/48), respectively (p = 1.000). For the post-ESD and peptic stricture groups, the clinical success rates (defined as symptom improvement, as determined by the patient) at 1 month were 92.9% (13/14) and 83.3% (40/48), respectively (p = 0.67). Their clinical success rates at 6 months were 71.4% (10/14) and 70 % (28/40), respectively (p = 1.000). The mean weight gains of the post-ESD stricture group 1 and 6 months after balloon dilation were 1.1 and 4.8 kg, respectively, whereas the peptic group gained 1.4 and 3.4 kg, respectively (p = 0.814). All complications were perforations. The complication rates of the post-ESD and peptic stricture groups were 7.1 % (1/14) and 10.5 % (5/48), respectively (p = 1.000).
  
  
  CONCLUSIONS
  Balloon dilation is an effective and safe treatment for post-ESD strictures.
authors.affiliation: Department of Gastroenterology, Asan Digestive Disease Research Institute, Asan Medical Center, University of Ulsan College of Medicine, No. 388-1 Pungnap-2 dong, Songpa-gu, Seoul 138-736, Korea. hkna77@naver.com
authors.forename: Hee Kyong
authors.initials: HK
authors.lastname: Na
authors.forename: Kee Don
authors.initials: KD
authors.lastname: Choi
authors.forename: Ji Yong
authors.initials: JY
authors.lastname: Ahn
authors.forename: Hyun
authors.initials: H
authors.lastname: Lim
authors.forename: Mi-Young
authors.initials: MY
authors.lastname: Kim
authors.forename: Jeong Hoon
authors.initials: JH
authors.lastname: Lee
authors.forename: Kwi-Sook
authors.initials: KS
authors.lastname: Choi
authors.forename: Do Hoon
authors.initials: DH
authors.lastname: Kim
authors.forename: Ho June
authors.initials: HJ
authors.lastname: Song
authors.forename: Gin Hyug
authors.initials: GH
authors.lastname: Lee
authors.forename: Hwoon-Yong
authors.initials: HY
authors.lastname: Jung
authors.forename: Jin-Ho
authors.initials: JH
authors.lastname: Kim
authors.forename: Jung Bok
authors.initials: JB
authors.lastname: Lee
mesh_terms: D000368:Aged; D003251:Constriction, Pathologic / Q000209:etiology / Q000628:therapy; D003287:Contrast Media; D004210:Dissection / Q000009:adverse effects*; D016099:Endoscopy, Gastrointestinal / Q000009:adverse effects*; D005260:Female; D005471:Fluoroscopy; D005767:Gastrointestinal Diseases / Q000209:etiology* / Q000601:surgery*; D006801:Humans; D007472:Iohexol / Q000031:analogs & derivatives; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D003287:Contrast Media; D007472:Iohexol; C038192:iopromide